Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Nov
11
Today In Oncology
Study Finds Gaps Exist in Quality of Cancer Care for Incarcerated People
Impact of Concomitant Noncancer Medications on Outcomes in Breast Cancer
NCCN Guidelines to Be Integrated Into OpenEvidence Medical AI Platform
Adding an Investigational Monoclonal Antibody to Ibrutinib May Allow Patients With CLL to Discontinue Daily Treatment
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo